Pakistan's retail pharmaceutical market touched a record Rs. 1.251 trillion (approx. $4.45 billion) in fiscal year 2026, registering a value growth of 14.88 percent year-on-year, according to data from the Drug Regulatory Authority of Pakistan (DRAP) and industry sources.
Despite the record valuation, total medicine unit sales rose by a mere 0.93 percent to 3.80 billion packs, down from 3.765 billion units previously, indicating severe pressure on household purchasing power and rising treatment costs.
| Fiscal Year | Market Size (Rs.) | Value Growth (%) |
|---|---|---|
| FY24 | 918.22 Billion | 22.40% |
| FY25 | 1.089 Trillion | 18.56% |
| FY26 | 1.251 Trillion | 14.88% |
National pharmaceutical companies dominated the market with Rs. 998.54 billion in sales (about 80% share) growing at 16.53 percent, whereas multinational companies recorded sales of Rs. 252.13 billion with a 6.16 percent drop in unit volume. Investors should note that while revenue is driven by pricing adjustments and higher-value drugs, sluggish volume growth highlights consumer constraints.
Read the full story on the original publisher’s website.
Open original article